Globally in 2017, an estimated 3.6 percent of new and 17 percent of previously treated TB cases had rifampicin-resistance (RR-TB) or multi-drug (combined rifampicin and isoniazid) resistant tuberculosis (MDR-TB) [WHO]. These cases require more complex treatment. To start, drug-susceptibility testing (DST) is recommended for all persons with signs and symptoms of TB. How is your country addressing drug-resistant TB?
Looking at Data
Take a look at the data in your country by following a series of questions. Share your insights at firstname.lastname@example.org.